Boryung Pharmaceutical Decides on 100 Billion KRW Paid-in Capital Increase

[Asia Economy Reporter Lee Junhyung] Boryung Pharmaceutical announced on the 19th that it has decided to conduct a paid-in capital increase to raise approximately 100 billion KRW in operating funds.

Accordingly, 5.55 million common shares will be newly issued. The par value per share is 500 KRW. The shares will be issued through a rights offering to existing shareholders followed by a general public offering for any unsubscribed shares.